BioPharmSignal logoBioPharmSignal

Biotech News

ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026

ADMA Biologics (ADMA)ADMA BiologicsConference / presentation

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Adam

Open original release

Related news

CHRSCoherus BioSciences, Inc.2026-01-06 14:30 EST

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

RXRXRecursion2026-01-06 12:59 EST

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

ADMAADMA Biologics2026-05-04 11:00 EST

ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older

ADMAADMA Biologics2026-04-29 11:00 EST

ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

IBIOIbio Inc2025-11-24 21:15 EST

iBio to Participate in the 8th Annual Evercore Healthcare Conference

IBIOIbio Inc2025-10-23 11:00 EST

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

MDXGMiMedx2026-05-21 12:45 EST

MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference

CHRSCoherus BioSciences, Inc.2026-02-23 14:30 EST

Coherus Oncology to Participate in Upcoming Investor Conferences

MDXGMiMedx2026-03-05 13:00 EST

MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields

View all latest news

ADMA Biologics

ADMA Biologics is a plasma-derived biologics company focused on immunoglobulin therapies and specialty immune products. Its business is centered on plasma supply, manufacturing, and commercial execution.

Recent company news

ADMAADMA Biologics2026-05-06 20:05 EST

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-05-04 11:00 EST

ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older

ADMAADMA Biologics2026-04-29 11:00 EST

ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

ADMAADMA Biologics2026-03-27 11:00 EST

ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research

ADMAADMA Biologics2026-03-25 10:30 EST

ADMA Biologics Addresses Misleading Short-Seller Report

Stock data

Close
8.48 USD
Market cap
1.76B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States